To validate these findings, and to search for additional susceptibility loci, we carried out a meta-analysis of our GWAS results and those from an independent European SLE GWAS comprising 1,165 cases and 2,107 controls (the Hom et al. 4 study). Each of the 25 loci mapped in the original GWAS had genome-wide significant p-values in this meta-analysis (Supplementary Table 1 ), and are therefore considered to be associated with SLE. We then designed a replication study, with inclusion based on the meta-analysis of the two GWA studies. At loci with no published association in SLE, we adopted a threshold for inclusion of P < 2.5 × 10 −05 , while for loci with previously reported associations the threshold was set at P < 1 × 10 −04 (see Online Methods for rationale). The 33 SNPs with P-values meeting these criteria were genotyped in our replication study (Supplementary Table 2 ), using a custom panel that also included 53 ancestry informative markers (see Online Methods). After applying QC measures, the replication data comprised 2,018 cases and 6,925 controls, none of which had been included in either GWAS (see Online Methods).
Finally, we carried out a post-replication meta-analysis of the results of our GWAS, the Hom et al. study and the replication study for those 33 SNPs, again applying the standard measure of genome-wide significance. The 18 SNPs (over and above the 25 already mapped) with Pvalues < 5 × 10 −08 in this meta-analysis were also considered to be associated with SLE (Table 1 and Supplementary Fig. 2b ). In addition to the three novel loci mapped in the GWAS, seven further variants, at loci hitherto not showing genome-wide significant association in SLE, were mapped in the overall meta-analysis: rs564799 (3q25.33), rs3794060 (11q13.4), rs10774625 (12q14.1), rs4902562 (14q24.1), rs9652601 (7q32.1), rs2286672 (17p13.2) and rs887369 (Xp21.2). The heritability explained by these 43 validated susceptibility alleles is 19.3% [95% C.I. 14.1-25.5%], where the total heritability of lupus is estimated to be 66% 16 . This is a large increase on the 8.7% [5.33-12 .96%] reported by So et al. 17 in 2011 using the same measure.
We imputed both the main GWAS and Hom et al. data to the density of the 1000 Genomes (1KG) study 18 and re-analyzed the data (see Online Methods). While no additional loci were identified, we did obtain stronger evidence in support of some loci, for example the signal at the SPRED2 locus, at which the most associated 1KG variant, rs268134, was strongly replicated. In addition, the imputation enabled us to fine map associated loci and to determine whether multiple signals were present ( Supplementary Tables 3a and 3b ). We identified multiple independent association signals at the TNFSF4, STAT4 and IRF5 loci, as well as five independently associated SNPs at the MHC (see below).
Given that the SNP with the smallest P-value is not necessarily the true causal variant, we considered SNPs from the most associated to a defined cut-off as potentially causal in our subsequent analyses. Specifically, guided by previous work on functional annotation 19 (see Online Methods), the cut-off was defined as a Bayes Factor against the most significantly associated SNP equal to 0.34. Any SNPs in this set that were missense variants were considered more likely candidates than the most associated SNP. The results are summarized in Supplementary Tables 3c and 4, listing candidate causal missense variants in PTPN22,  FCGR2A, NCF2, TNFAIP3, WDFY4, IRF7, ITGAM and TYK2. MHC polymorphisms, including SNPs and classical human leukocyte antigen (HLA) alleles, have consistently been observed to be associated with SLE 20 . We imputed HLA alleles 21 in both the main GWAS and Hom et al. data, and incorporated them into our analysis of 1KG imputed data across the MHC (see Online Methods). Of the five MHC SNPs we find to be independently associated with SLE ( Supplementary Tables 3a and 3b) , the class III SNP in SLC44A4 (rs74290525) is the only association signal that is clearly independent of any HLA alleles. We find that rs74290525 is significantly associated not only when conditioning on each of the HLA genes separately, but even when conditioning on all 199 HLA alleles (see Supplementary Tables 5a-e ), and is not in linkage disequilibrium (LD) with any HLA alleles (R 2 < 0.1 with each HLA allele). We find that the best model for association includes the HLA class I alleles B*08:01, B*18:01, the class II alleles DQB1*02:01, DRB3*02:00 and DQA*01:02, and the class III SNP rs74290525, consistent with previous findings suggesting multiple SLE associations at the MHC 20 ( Supplementary Tables 6a and 6b ). LD between the five MHC SNPs and HLA alleles on known SLE risk haplotypes can be seen in Supplementary Table 6c .
In order to highlight potential causal genes at the susceptibility loci, the associated SNPs at each of the loci were tested for correlation with cis-acting gene expression in ex vivo naïve CD4+ T cells, B cells, natural killer (NK) cells, and stimulated and resting monocytes [22] [23] [24] . Figure 1 displays a heat map across cell types, showing genes exhibiting significant differential expression in relation to the SLE associated alleles. We calculated Regulatory Trait Concordance (RTC) scores 25 (see Supplementary Figs. 3a and b) to test the relationship between eQTLs driven by disease-associated alleles, and other, potentially stronger eQTLs, which we identified at each locus. The cis eQTLs were distributed across all cell types tested, some being common to all cell types, such as UBE2L3 and UHRF1BP1, while others are more cell specific: BLK in B cells and JAZF1 in T cells. In general directionality was consistent, although not in all cases: for example ABHD6 showed reduced expression in monocytes and elevated expression in lymphocytes.
We note that some caution must be used when inferring causality, as the RTC score has a uniform distribution and so setting an RTC score threshold of 0.9 for example, sets the type I error rate to be 0.1. Furthermore, some low RTC scores were found in genes (e.g. UBE2L3)
where the associated allele resides in a region with strong LD, and the haplotype bearing the associated allele shows robust evidence of functional effects on gene expression 26 . We suggest that the gene expression analyses provide some support for likely causal genes, but we note that proof of true causality through altered gene expression will only be elucidated by additional experimentation.
We then integrated the results of these eQTL analyses and the coding variant analysis with an in silico survey of murine phenotype data resulting from targeting gene knockouts of genes within the associated SLE loci ( Table 2) . At some loci, these lines of evidence point to one likely causal gene: examples include IFIH1, LYST, WDFY4 and BANK1. In other instances, we found evidence that supports the role of multiple genes as candidates at a given locus; for example, ABHD6 (an enzyme involved in the endocannabinoid pathway) and PXK (a lymphocyte protein kinase) 3 both exhibit correlation of their expression with the associated SNP. Similarly, TCF7 (coding a T cell transcription factor), implicated by the rs7726414 association, has been associated with type 1 diabetes 27 ; however, we show that SKP1 (which encodes a protein involved in the regulation of ubiquitination), within the same LD block exhibits a strong cis eQTL in monocytes and NK cells. rs9652601 resides within CLEC16A, a gene previously reported in association studies in other autoimmune diseases 28 ; we present evidence suggesting that SOCS1 (Suppressor of Cytokine Signaling 1) is a causal gene at this locus in SLE rather than CLEC16A. Our analyses have the advantage of including cis eQTLs based on ex vivo cells, rather than cell line data alone.
Nevertheless, we acknowledge the restricted range and activation states of immune cell types available for eQTL analyses and the limited number of murine and other functional studies performed on genes at the loci.
The 10 previously unmapped SLE loci (shown in bold type in Table 1 and Supplementary  Table 3a ) encompass genes of diverse function. Those of note include IKZF2 (Helios), which represents the third member of the Ikaros transcription factor family to be associated with SLE (in addition to IKZF1 and IKZF3). The association signal in the phospholipase D2 (PLD2) is a missense variant (R172C), which may alter the function of the enzyme that plays a role in leukocyte migration and apoptosis. The importance of IL12, a cytokine that plays a critical role in the generation of γ-interferon from Th1 T cells and NK cells, is highlighted by the association with IL12A (Table 1) , and the suggestive associations at IL12B and the locus encoding the IL12 receptor, IL12RB2 (Supplementary Table 2 ).
In view of the sexual dimorphism of SLE, the novel X chromosome association revealed by rs887369 is of note. We suggest that the gene CXorf21 is likely to be etiological. While the function of this gene is unknown, it is among a limited set of genes that largely escape Xinactivation 29 . Sex chromosome dosage has been implicated in the genetic risk of SLE 30 . We observed an elevated prevalence of Klinefelter's syndrome 31 in male cases in our GWAS compared with the general population (see Online Methods) strengthening the sex chromosome dosage hypothesis. The only other gene close to rs887369 (Table 2) is GK (glycerol kinase) which does not escape X-inactivation, supporting CXorf21 as a candidate gene.
Five other genes (TNIP1, IKZF1, ETS1, WDFY4 and ARID5B) that we mapped are novel in European SLE, but had been previously shown to be associated with SLE in Chinese subjects 5, 6 . SLE is more prevalent in non-European populations -our data suggest that locus heterogeneity among common genetic variants is unlikely to explain this differential prevalence.
We present all of our principal findings in Fig. 2 . This figure indicates ten likely missense coding variants that contribute to SLE risk; these occur largely in genes encoding kinases and other enzymes. It was noted that 16 of the genes shown are transcription factors, an enrichment above the nine expected (P = 2.3 × 10 −05 , χ 2 test). We studied the distribution of the expression of these transcription factors in the ex vivo immune cell types examined for eQTLs; we found no evidence of skewed expression in any cell type. Our results suggest that an important facet in future exploration of SLE pathogenesis will be detailed scrutiny of trans eQTLs and regulatory expression networks in multiple immune cells.
ONLINE METHODS

Data: genome-wide association study (GWAS)
We genotyped 4,946 SLE cases and 1,286 healthy controls using the Illumina HumanOmni1-Quad BeadChip (1,140,419 markers). The genotyped controls were mostly from southern Europe, matching our Spanish, Italian and Turkish cases with controls from the same countries. We also used data for 5,727 previously genotyped controls taken from the University of Michigan Health and Retirement Study (HRS). These subjects were genotyped using the Illumina Human2.5M Beadchip (2,443,179 markers).
The clinical features of our GWAS cohort were documented on the basis of standard ACR classification criteria. The experiment was designed to avoid batch effects to the greatest extent possible. All DNA samples were sent to the laboratory at King's College London, UK, where the integrity of the DNA was checked. The GWAS samples were then genotyped at a single laboratory. All data analysis was carried out in the laboratory at King's College.
Genotyping for the GWAS was carried out using 82 plates, processed in 13 batches. Duplicate samples taken from HapMap Phase 3 were added to each plate to check genotyping quality. Case-control status and country of recruitment were randomized across plates as far as possible, in order to avoid artifactual differences in genotyping between plates affecting association statistics.
Our final dataset comprised genotyping of 644,674 SNPs for 4,036 SLE cases and 6,959 controls (1,260 controls of mainly southern European ancestry and 5,699 from the HRS).
Data: Hom et al. study
We analyzed data from a previous genome-wide association study of SLE (the Hom et al. study), which comprised 1,165 cases following our QC analysis (see Supplementary Text). We used a further 2,107 previously genotyped controls from the NIH CGEMS study, which were genotyped using the Illumina HumanHap550 chip. Owing to the lower density of genotyping, in some cases data imputed to the density of the 1000 Genomes (1KG) study were used in the analysis of the Hom et al. study and the subsequent meta-analysis. Imputed data are identified in tables.
Data: replication study
A cohort of 2,310 cases not included in any previous genetic study of SLE was genotyped using a custom array. The largest group of samples was from the UK, followed by cohorts from France, the USA, Germany and Canada.
The control data for the replication study comprised 3,672 subjects from the HRS cohort (independent of those used in the GWAS), 3,102 subjects from a study of melanoma and 1,202 subjects from a study of blood clotting. These control data were genotyped using the Illumina 2.5M chip. Following QC procedures (Supplementary Text), the final control dataset comprised 6,925 individuals: 3,668 from the HRS, 2,889 from the melanoma study and 368 from the blood clotting study. The final case dataset consisted of 2,018 samples.
In some cases, SNPs identified by our GWAS as genome-wide significant were not present in the replication control data (owing to absent genotyping in one of the three control sets following QC), and so genotypes for those SNPs were imputed (see below). Again, we identify these SNPs in our results tables.
Ethical approval
The UK subjects with SLE in the study were recruited with the study having obtained ethical approval from the London Ethics Committee (MREC/98/2/06 and 06/MRE02/9). Individuals were invited into the study and given information sheets as well as verbal explanations of what the research entailed. For those individuals willing to participate informed written consent was obtained. The recruitment in continental Europe and Canada were subject to local review and ethical approval. Copies of the relevant supporting documentation were sent to the investigators at King's College at the commencement of the study.
Quality control
Initial QC analysis of the genotype data was carried out in accordance with Illumina's Technical Note on Infinium Genotyping Data. In silico QC checks were carried out of: IBD analysis included checks both within and across cohorts; no subject in the main GWAS or Hom et al. study is related to any other subject in either cohort. We calculated principal components for the GWAS data using the EIGENSTRAT algorithm 12 , and derived the empirical genomic inflation factor 13,69 for these data. As noted by Price and colleagues 14 , the definition of genomic control means that λ GC is proportional to sample size. We therefore report λ 1000 , the inflation factor for an equivalent study of 1000 cases and 1000 controls 15, 70 , in the main text, as well as λ GC .
For the replication cohort, population structure was estimated using 46 ancestry informative markers (following QC measures on these SNPs). As described in Supplementary Text, we merged these data with HapMap data to help identify non-European samples. Again, principal components were calculated using the EIGENSTRAT algorithm. 120 subjects that clustered with the non-European HapMap populations were removed from the analysis.
Klinefelter's syndrome
During QC analysis, we identified subjects in our GWAS cohort with abnormal karyotypes, consistent with Klinefelter's syndrome (47, XXY 
Analysis: association
All case-control analysis was carried out using the SNPTEST 71,72 algorithm; we use a standard threshold of P = 5 × 10 −8 for reporting genome-wide significance throughout. The inverse variance method was used for meta-analysis. All markers were fully genotyped in the main GWAS (i.e, no imputation was carried out). The imputation carried out for the Hom et al. and replication studies, and fine mapping imputation, are described below.
For all SNPs at which we report a novel association with SLE, we compared allele frequencies in the main GWAS controls with those in publically available control cohorts (1KG European samples 18 , Wellcome Trust Case Control Consortium (WTCCC) genotypes 73 , TwinsUK samples, HapMap CEU population data, and sample genotypes from the Knight laboratory expression data 23 ). We tested for a statistically significant (α = 0.01) difference in allele frequency between our GWAS and the public controls, using a 1 degree of freedom χ 2 test of allele frequencies. One SNP failed this test (rs1439112, MGAT5) and
was removed from further analysis. In three further cases, the difference in allele frequency strengthened our observed association. These data are presented in Supplementary Table 7 .
Annotation of results
Gene names listed in results tables were identified by overlaying GWAS results onto the UCSC Genome Browser. We adopted a threshold based on linkage disequilibrium: for each SNP, we noted the set of markers with R 2 > 0.75 with respect to the SNP of interest ( Table  2) .
Post hoc QC
Checks carried out following case-control analysis included examination of plots of raw genotype intensity; this was of particular relevance given the increase in the numbers of relatively rare variants due to the higher density of genotyping (as with imputation, genotype calling is by definition more difficult for rarer variants). We checked that the intensity plots showed clusters of genotypes (i.e., homozygotes or heterozygotes) that were compact and well discriminated. This check was also carried out with stratification by QC group. Plots of intensity were examined for each associated SNP, and for all of the SNPs in the replication study.
Analysis: replication study chip design
We selected SNPs for the replication study based on the results of the meta-analysis of the two GWA studies. At loci with no known association in SLE, we adopted a threshold of P = 2.5 × 10 −05 , while for loci with previously reported associations the threshold was set at P = 1 × 10 −04 . This followed the methodology used in Box 1 of the WTCCC study of seven common diseases 73 . This declared SNPs as associated if the posterior odds of association were greater than 10. In that study, the assumption was made that 10 detectable genes were present, so the prior odds of a true association would be in the order of 100,000:1, assuming 1,000,000 independent regions in the genome. Based on the autoimmune genetics literature, we have assumed that there are likely to be as many as 500 genes associated with SLE. We have required posterior odds in favour of a SNP being associated to be >1 (as opposed to >10, which would be advisable if declaring an association rather than choosing SNPs for replication). This gives a P-value threshold of 2.5 × 10 −05 . For SNPs at loci with previously published SLE associations, we have reduced our threshold for inclusion in the replication study to P = 1 × 10 −04 . This is because a priori we believe these SNPs are more likely to be at susceptibility loci than those with no evidence of association, increasing the prior odds by at least a factor of 4.
Analysis: 1000 Genomes (1KG) imputation
For imputation, both the main GWAS and the Hom et al. data were pre-phased using the SHAPEIT algorithm 74 , and then imputed to the density of the 1KG study using IMPUTE 71,72 v2.2.3. Only markers with an IMPUTE INFO score > 0.7 were used in analysis. For SNPs identified in our GWAS as genome-wide significant at which data were absent in the replication study controls, we imputed over a +/-1Mb region around the SNP of interest.
1KG data were used both to fine map loci and to determine whether multiple signals were present. For this analysis, we carried out a meta-analysis of 1KG imputed GWAS and Hom et al. data. Association testing was performed on the 1KG data within a 1 Mb window of the reported SNP. For the MHC, we included the complete 8 Mb region (26-34 Mb) in our analysis. To scan for further independent signals, association tests were performed including the genotype data for the most highly associated SNP as a covariate. If secondary signals were found to be associated by this analysis (with a P-value threshold of 5 × 10 −08 ) and odds ratios were consistent across the single marker and conditional analyses, the secondary signals were reported as independent associations.
In order to address the problem that the most associated (lead SNP, marker with the lowest p-value) variant is not necessarily the best candidate as the true causal variant, we considered markers from the most associated down to a defined cut-off. The cut-off was defined as a Bayes Factor (BF) against the most associated SNP equal to 0.34. This was derived from assuming a prior odds of causality for a non-synonymous SNP equal to 3, taken from an empirical analysis of GWAS annotation 19, 75 . Any SNPs above this BF cut-off that were missense variants were declared as more likely candidates than the most associated SNP: assuming that the prior odds of a missense SNP (being causal) against a non-missense SNP to be equal to 3, any missense SNP with a BF > 0.34 will have a posterior odds > 1 and will therefore have a higher posterior probability than the most associated marker (if the most associated marker is non-missense). Therefore we searched for functional variants within a set of markers where inclusion in this set required a maximum Bayes factor (BF) > 0.34 between the marker and the most associated SNP in the 1KG imputed data. We considered any marker that had a BF > 0.34 with respect to the most associated marker, and noted whether any had functional effects. We calculated an approximate BF following Wakefield 76 , using a prior distribution on effect size (odds ratio) that was proportional to MAF (as rare variants are believed to have large effects, while common variants are believed to exert small effects). The BF threshold implies that we believe associations with functional variants, such as missense variants, three times more (say) than intergenic variants that do not correlate with gene expression. We then calculated posterior model probabilities following Maller et al. 77 , but with prior odds of 3 between missense SNPs and non-missense SNPs; Maller et al. use a uniform prior on all model probabilities (all SNPs are considered to have equal weights a priori, and therefore the prior odds are 1). We present these results in Supplementary Table 4 where we also, separately, display SNPs with a BF > 0.1 (as a strict threshold of 0.34 does not reflect the uncertainty in prior odds of causality and BF estimates). We also calculated the BF between SNPs presented in Table 1 and the SNPs listed in Supplementary Table 3a and declared that the marker for association had changed if the BF was greater than 10 (equal to "strong" evidence on the Jeffreys' scale 78 ). These SNPs are annotated in Supplementary Table 3a .
Analysis: the MHC and HLA alleles
We included imputed HLA alleles in analysis of the MHC, allowing us to determine the most likely model of association within this region. HLA imputation was performed using HLA*IMP V2 21 using genotyped SNP data. To determine the best model for association within the HLA alleles alone we ran forward stepwise regression. We then tested the five SNPs listed in Supplementary Tables 6a-c for association, conditional on the HLA alleles.
To test whether each of the five SNPs was independent of the HLA alleles (rather than just the alleles in the best HLA model), we carried out a test conditional on all alleles (i.e., the HLA alleles were used as covariates) in each HLA gene, and for all HLA alleles over all genes. We used a significance threshold at each stage of the stepwise regression of P = 5 × 10 −05 , which is a Bonferroni adjustment for 204 tests (199 HLA alleles and 5 SNPs), with a familywise Type I error rate of 0.01.
Analysis: gene expression data
Gene expression data were obtained from three sources: firstly, we obtained data from Fairfax et al. 22 To test whether observed associations between SNPs and expression levels of cis-acting genes were purely due to chance, we calculated the RTC score 25 for all SNP-gene eQTL results displayed in the heat map (Figure 1 ). This tests the null hypothesis that the GWAS associated SNP and the best eQTL (within a recombination hotspot) are tagging two separate effects, and the observed eQTL is purely due to the LD between the GWAS associated SNP and the "true" eQTL SNP. For our data, we were interested in the distribution of RTC scores, given that eQTL results were generated in multiple cell types. Not all eQTLs were consistently present across all these cells. We therefore plotted the RTC scores against the -log 10 P-values supporting each cis eQTL in all cell types ( Supplementary   Figures 3a and 3b) . Supplementary Figures 3a and 3b show that three genes were outlying: ITGAM in two cell types, and UBE2L3 and PLD2 in CD4 cells. However, we have strong a priori evidence of a true causal effect on expression by polymorphisms around UBE2L3 26 .
For ITGAM, we note the low RTC scores in Figure 1 , which includes all eQTL data for ITGAM given that the results are convincing for the eQTL in LPS stimulated monocytes (P = 2.67 × 10 −19 and RTC = 0.85). We have removed the declaration of an eQTL for PLD2. Supplementary Figure 4 displays a heat map for these data using a t-statistic.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Heat map for cis-acting gene expression RTC scores from ex vivo cells. The heat map includes all genes with evidence of cis-regulatory (+/-1Mb) action by SLE associated SNPs in at least one cell type. The color represents a signed-RTC-score: a positive score indicates that the associated allele in the GWAS is positively correlated with gene expression; a negative score indicates that the associated allele in the GWAS is negatively correlated with gene expression. We set the RTC score to zero if the P-value for association was > 0.001.
Colors represent the RTC-scores as follows: blue, RTC < -0.9 (GWAS risk allele reduces expression); green, RTC < -0.5 (GWAS risk allele reduces expression); yellow -0.5 < RTC < 0.5; orange, RTC > 0.5 (GWAS risk allele increases expression); red, RTC > 0.9 (GWAS risk allele increases expression). A white block indicates that data were not available for this cell type (see Supplementary Figure 4 for results on lymphoblastoid cell lines), either because the probe data failed QC or the probe was not present in the experiment platform.
Clustering was performed on cell types, including only genes with data observed for all cell types (i.e., missing data did not inform cell clustering). Genes were clustered using all available data across cells (missing data were not included when determining distance between pairs of genes if eQTL results were not observed for one of the pairs). C17orf37  GRB7, IKZF3,  ZNFN1A3  ZBPB2, GSDMB   IKZF3   IKZF3   66   IKZF3   rs2304256   19  DNMT1, S1PR2, MRPL4, ICAM1,  ICAM4 ICAM5  ZGLP1, FDX1L, RAVER1, ICAM3,  TYK2, CDC37  PDE4A, KEAP1, S1PR5, ATG4D,  KRI1   TYK2   DNMT1,  S1PR2  ICAM1, S1PR5  TYK2   TYK2   TYK2, ICAM3   TYK2   67   TYK2   rs7444 The MHC is not included due to extended LD and gene density at the locus
